OptimizeRx Corporation — Earnings Quality Grade C
OPRX · Healthcare
Some red flags
Screening Summary
Management Signals
Financial Trends
Revenue & Net Income ($B)
Margins (%)
18-Point Screening
Revenue Quality
DSO 126 days, change -25 days YoY
AR growth -1.2% vs revenue growth 18.8%
Revenue 18.8%, CFFO 282.8%. Cash follows revenue
Expense Quality
No material inventory
Insufficient data
SG&A/Gross Profit = 77.7%, exceeds 70%
Gross margin 67.3%, change +2.8pp. Stable
Cash Flow Quality
CFFO/NI = 3.65. Profits backed by cash
FCF $0.0B, FCF/NI = 3.65
Accruals ratio = -7.7%. Low accruals
Cash $0.0B covers 90% of debt $0.0B
Balance Sheet Health
Goodwill+Intangibles $0.1B = 87% of equity. Over 50%
Debt/EBITDA = 1.6x. Healthy
Other assets -90.5% vs revenue 18.8%. Normal
No write-off data
Acquisition Risk
FCF after acquisitions positive
Goodwill+Intangibles change -4% YoY. Normal
Manipulation Score
M-Score = -2.79 (< -2.22). Unlikely manipulator
Portfolio monitoring
Monitor OPRX continuously
The full checks and model details are free to read. Use Watchlist to track your holdings; Pro adds automatic quarterly rescoring, risk-event email alerts, scans up to 50 tickers, and export workflows.
Beneish M-Score
Altman Z-Score
Generated from public financial data using forensic accounting frameworks. Not investment advice. Data: Yahoo Finance · 2026-04-25